Restore Vision Reports Encouraging Early Results for Retinitis Pigmentosa Gene Therapy

Restore Vision Inc. has released positive interim findings from its initial human clinical trial of RV-001, a gene therapy for advanced Retinitis Pigmentosa. The study observed no significant safety concerns across dose cohorts. Notably, individuals in the high-dose group, who initially had no light perception, showed improved light perception within one month of treatment, indicating potential for visual improvement.